NCT06765005View on ClinicalTrials.gov

IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

July 19, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

July 31, 2025

Conditions

Atopic Dermatitis

Interventions

DRUG

MG-K10

Subcutaneous injection, once every 4 weeks

Trial Locations (1)

310000

RECRUITING

Hangzhou First People's Hospital;, Hangzhou

All Listed Sponsors

lead

Shanghai Mabgeek Biotech.Co.Ltd

OTHER_GOV